SEC Form 4 · accession 0001628280-26-047710
Contineum Therapeutics, Inc. · CTNM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carmine N. Stengone
Officer — CEO and President · Director
Period of report
Jul 8, 2026
Accepted (ET)
Jul 8, 2026 · 6:49 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001855175
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Jul 8, 2026 | M | 2,500 | $1.01 | A | 19,717 | D | |
| Class A Common Stock | Jul 8, 2026 | S | 2,500 | $16.00 | D | 17,217 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $1.01 | Jul 8, 2026 | M | 2,500 | D | — | Feb 24, 2030 | Class A Common Stock | 2,500 | 279,430 | D |
Explanation of responses
- F1These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- F2Options granted under the Issuer's 2012 Equity Incentive Plan (the "Plan"). The option is fully vested.